once-weekly semaglutide in adults with overweight or obesity pubmed Once-Weekly Semaglutide in Adolescents with

Continuing this discussion, we broaden the lens to the developing litigation environment and additional regulatory scrutiny that can affect manufacturers, pharmacies, telehealth providers, and other stakeholders across the GLP1 ecosystem

A weight management doctor answers questions about what happens when someone stops taking weight loss medications such as semaglutide or tirzepatide.

The demand for semaglutide (Wegovy, Ozempic) and similar weight-loss drugs has renewed interest in the dietary supplement berberine

The weight loss market is undergoing a seismic shift as the focus moves from injectable peptides to oral small molecule GLP-1 receptor agonists, led by Eli Lillys promising candidate, orforglipron

This image cannot and should not be taken seriously, and does not constitute medical advice.

Are you tired of trying to shed those stubborn pounds with little to no success